NCT06600906View on ClinicalTrials.gov

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

RecruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

August 1, 2030

Study Completion Date

September 1, 2032

Conditions
Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Hyperpolarized 13C-Pyruvate

Given intravenously (IV)

PROCEDURE

Computed tomography (CT)

Undergo CT imaging

PROCEDURE

Magnetic Resonance Imaging (MRI)

Undergo MRI imaging

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER